No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CLB240816C22500
- 1.05
- -1.45-58.00%
15min DelayClose Jul 22 15:59 ET
1.05High0.85Low
0.85Open2.50Pre Close35 Volume59 Open Interest22.50Strike Price3.41KTurnover27.04%IV4.07%PremiumAug 16, 2024Expiry Date0.13Intrinsic Value100Multiplier25DDays to Expiry0.92Extrinsic Value100Contract SizeAmericanOptions Type0.5665Delta0.2445Gamma30.17Leverage Ratio-0.0144Theta0.0083Rho17.09Eff Leverage0.0234Vega
Intraday
- 5D
- Daily
News
What's in Store for Core Laboratories (CLB) in Q2 Earnings?
Core Laboratories (CLB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BofA Securities Maintains Core Laboratories(CLB.US) With Sell Rating, Cuts Target Price to $15
BofA Securities analyst Saurabh Pant maintains $Core Laboratories(CLB.US)$ with a sell rating, and adjusts the target price from $16 to $15.According to TipRanks data, the analyst has a success rate
Core Labs Is Maintained at Neutral by Piper Sandler
Core Labs Is Maintained at Neutral by Piper
Core Labs Price Target Cut to $17.00/Share From $18.00 by Piper Sandler
Core Labs Price Target Cut to $17.00/Share From $18.00 by Piper
Piper Sandler Maintains Neutral on Core Laboratories, Lowers Price Target to $17
Piper Sandler analyst Luke Lemoine maintains Core Laboratories with a Neutral and lowers the price target from $18 to $17.
Comments
Core Laboratories' declining ROCE trend signals a mature business possibly facing new competition or smaller margins. Unless metrics shift positively, consider other investment opportunities.
Analysts are more negative on Core Laboratories after recent results, leading to a minor EPS downgrade for next year. Despite this, the unchanged consensus price target suggests lower forecast earnings won't affect the stock price. However, the company's revenue growth is expected to lag the industry average.
Despite Core Laboratories' move to profitability, the ongoing drop in revenue and share price indicates negative market sentiment. Investors are urged to consider other factors before investing.
Investors project strong growth for Core Laboratories given the high P/E ratio, showing confidence in the company's future earnings. Other investment risks should also be considered while investing, not just the P/E ratio.
Read more